Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 179,946,176
  • Shares Outstanding, K 2,735,160
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.81
  • Price/Sales 4.53
  • Price/Cash Flow 11.38
  • Price/Book 4.54

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.43 +7.10%
on 08/21/17
66.41 -0.93%
on 09/18/17
+4.30 (+6.99%)
since 08/18/17
3-Month
61.16 +7.57%
on 08/18/17
66.41 -0.93%
on 09/18/17
+1.26 (+1.95%)
since 06/20/17
52-Week
58.29 +12.87%
on 11/03/16
66.80 -1.51%
on 03/01/17
+3.85 (+6.22%)
since 09/20/16

Most Recent Stories

More News
New First Line Treatment Now Available for Canadians with Metastatic Non-Small Cell Lung Cancer

Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that KEYTRUDA(®) (pembrolizumab) as monotherapy is now indicated for the treatment of metastatic non-small cell lung...

MRK : 65.79 (-0.24%)
Roche (RHHBY) Announces Positive Data on Leukemia Drug

Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.

CELG : 144.24 (+0.54%)
MRK : 65.79 (-0.24%)
ABBV : 87.41 (+1.20%)
RHHBY : 31.9500 (+0.60%)
Orphan Technologies Applauds Margaret McGlynn for Trailblazer Lifetime Achievement Award

Orphan Technologies, a Company dedicated to helping patients control their homocysteine levels, today recognizes Margaret G. McGlynn for receiving the Trailblazer Lifetime Achievement Award....

FOLD : 14.92 (+6.88%)
MRK : 65.79 (-0.24%)
Pro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Merck, Jim Kelly and Leading Cancer Organizations To Expand Your Cancer Game Plan To Help More People Impacted by Cancer

Pro Football Hall of Famer Jim Kelly and Pro Baseball Hall of Famer Mike Schmidt - two legendary athletes whose determination, faith and hard work earned them a place in sports history -...

MRK : 65.79 (-0.24%)
Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks' Azymetric(TM) Platform into Preclinical Development

Zymeworks Inc. ("Zymeworks"), (NYSE: ZYME; TSX: ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific...

MRK : 65.79 (-0.24%)
ZYME : 7.93 (-3.88%)
ZYME.TO : 10.25 (+2.50%)
Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA

Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.

CELG : 144.24 (+0.54%)
MRK : 65.79 (-0.24%)
RHHBY : 31.9500 (+0.60%)
BMY : 63.49 (+0.89%)
LifeMine Therapeutics Launches with $55 Million Series A Financing

LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round was led by WuXi Healthcare Ventures with an investor syndicate comprised of Foresite Capital, GV (formerly...

MRK : 65.79 (-0.24%)
BELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models

- BELLUS to provide BLU-5937 program update during September 20(th) webcast -- Key Opinion Leader Dr. Jacky Smith to present on chronic cough -

MRK : 65.79 (-0.24%)
BLU.TO : 0.43 (unch)
Merck Announces Recipients of the Grant for Growth Innovation 2017

DARMSTADT, Germany, September 18, 2017 /PRNewswire/ --

MRK : 65.79 (-0.24%)
Oncology Space in Focus this Week on ESMO Presentations

There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.

AZN : 32.93 (+0.80%)
MRK : 65.79 (-0.24%)
TEVA : 17.11 (-0.47%)
RHHBY : 31.9500 (+0.60%)
PFE : 35.99 (+1.52%)
BMY : 63.49 (+0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 66.88
1st Resistance Point 66.34
Last Price 65.79
1st Support Level 65.22
2nd Support Level 64.64

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.